Management of Decreased Libido in Females
Begin with a systematic assessment of contributing factors including vaginal symptoms, psychological distress, medication side effects, and hormonal status, then treat with vaginal moisturizers/lubricants as first-line for vaginal dryness, psychosexual therapy for psychological components, and consider flibanserin for premenopausal women with hypoactive sexual desire disorder or DHEA supplementation for postmenopausal women with persistent symptoms. 1
Initial Assessment
Screen for Underlying Contributors
Evaluate for menopausal symptoms including vaginal dryness, dyspareunia, and other vaginal issues that directly contribute to decreased sexual desire 1
Assess psychological factors including distress, anxiety, depression, body-image concerns, and relationship issues, as these commonly affect libido 1
Review all medications, particularly antidepressants, which frequently impair libido as a side effect 1
Consider hormonal status: Premenopausal versus postmenopausal women require different management approaches 2
Important Caveat on Testosterone Testing
- Do not routinely obtain testosterone levels in women in non-research settings, as this is not recommended even when decreased libido is present 3
Treatment Algorithm
First-Line: Address Vaginal Symptoms
Use vaginal moisturizers, lubricants, and gels as the initial treatment for vaginal dryness and dyspareunia that contribute to low libido 1
These non-hormonal options are particularly important for breast cancer survivors and women on aromatase inhibitors, who experience higher rates of vaginal atrophy (18% vs 8% with tamoxifen) 3
Second-Line: Psychosexual Therapy
Implement psychosexual therapy either alone or combined with physical therapies, which demonstrates successful outcomes in 50-80% of patients 1
This approach is especially critical when body image concerns, relationship issues, or cancer-related psychological trauma contribute to sexual dysfunction 3
Pharmacologic Options
For Premenopausal Women
Flibanserin (ADDYI) is FDA-approved specifically for acquired, generalized hypoactive sexual desire disorder in premenopausal women 1, 2
Critical safety requirements with flibanserin:
- Take only at bedtime (100 mg once daily) 2
- Absolutely no alcohol consumption close to bedtime dosing or until the following day, as this significantly increases risk of severe hypotension and syncope 2
- Contraindicated with moderate or strong CYP3A4 inhibitors (including certain HIV medications, antifungals, antibiotics, and grapefruit juice) 2
- Contraindicated in women with liver problems 2
- Not for use during breastfeeding 2
For Postmenopausal Women
Consider DHEA supplementation (10-50 mg daily) for persistent lack of libido and/or low energy levels in postmenopausal women 1
This addresses the androgen deficiency that commonly occurs after menopause and contributes to decreased sexual drive 4
Special Populations
Cancer Survivors
Include sexual health in survivorship care plans, as this is frequently overlooked despite affecting at least 50% of women after breast cancer 3, 1
Sexual dysfunction in cancer survivors is multifactorial: chemotherapy causes fatigue and decreased desire, endocrine therapy produces profound estrogen deprivation effects, and surgery impacts body image 3
Avoid hormonal contraception in breast cancer survivors; use alternative non-hormonal methods instead 1
Women on Aromatase Inhibitors
Aromatase inhibitors cause more severe vaginal dryness (18%) compared to tamoxifen (8%) because they inhibit peripheral androgen-to-estrogen conversion by >95% 3
These women require aggressive management of vaginal symptoms with non-hormonal moisturizers and lubricants 3, 1
Common Pitfalls to Avoid
Do not dismiss decreased libido as "normal aging": Both premenopausal and postmenopausal women can have hypoactive sexual desire disorder requiring treatment 5
Do not prescribe flibanserin without ensuring the patient understands alcohol restrictions: The combination causes severe hypotension and syncope 2
Do not overlook medication-induced sexual dysfunction: Systematically review all medications, especially antidepressants and hormonal therapies 1
Do not focus solely on biological factors: The etiology is multifactorial, requiring assessment of psychological, relational, and physical components 4, 5
budget:token_budget Tokens used this turn: 4857 Total tokens used: 4857 Tokens remaining: 195143